{"success":true,"data":{"pressRelease":{"id":"101932","rtpr_id":"nGNX8sTRmH","ticker":"LBRX","exchange":"NASDAQ","all_tickers":["LBRX"],"title":"LB Pharmaceuticals Announces $150 Million Private Placement","author":"Globe Newswire","published_at":"2026-07-29T12:00:01.082Z","article_body":"NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB\nPharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines\ncompany dedicated to developing and commercializing high-impact therapies that\naddress the multiple dimensions of underserved brain diseases, today announced\nthat it has entered into a securities purchase agreement to sell 3,577,560\nshares of its common stock and pre-funded warrants to purchase up to 715,513\nshares of its common stock to a limited group of institutional investors in a\nprivate placement. The purchase price of each share of common stock is $34.94.\nThe purchase price of each pre-funded warrant is $34.9399, which represents\nthe per share purchase price for the common stock less the $0.0001 per share\nexercise price for such pre-funded warrant. LB Pharmaceuticals anticipates the\ngross proceeds from the private placement to be approximately $150 million,\nbefore deducting any transaction-related expenses. The private placement is\nexpected to close on or about July 30, 2026, subject to the satisfaction of\ncustomary closing conditions.\n\nThe financing includes participation from new and existing institutional\ninvestors, including Adage Capital Partners, L.P., BB Biotech, Caligan\nPartners, Commodore Capital, Deep Track Capital, funds managed by Farallon\nCapital Management, Integral Health Asset Management, Janus Henderson\nInvestors, Spruce Street Capital, StemPoint Capital LP, a leading mutual fund\nand other investors.\n\nLeerink Partners and Piper Sandler acted as placement agents for the private\nplacement.\n\nLB Pharmaceuticals intends to use the net proceeds from the private placement\nto fund pipeline expansion of LB-102 into new indications with strong\nmechanistic rationale and validating clinical and real-world experience from\namisulpride, potentially including negative symptoms of schizophrenia and\nAlzheimer’s disease agitation/psychosis, and for working capital and general\ncorporate purposes.\n\nThe offer and sale of the securities to be sold in the private placement have\nnot been registered under the Securities Act of 1933, as amended (the\n“Securities Act”), or any state or other applicable jurisdiction’s\nsecurities laws, and such securities may not be offered or sold in the United\nStates absent registration or an applicable exemption from the registration\nrequirements of the Securities Act and applicable state or other\njurisdictions’ securities laws. Concurrently with entering into the\nsecurities purchase agreement, LB Pharmaceuticals and the investors entered\ninto a registration rights agreement pursuant to which LB Pharmaceuticals has\nagreed to file a registration statement with the Securities and Exchange\nCommission registering the resale of the shares of common stock issued in the\nprivate placement, including the shares of common stock underlying the\npre-funded warrants.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any jurisdiction in which such offer, solicitation or sale would\nbe unlawful prior to the registration or qualification under the securities\nlaws of any such jurisdiction.\n\nAbout LB-102\n\nLB-102 is a novel, once-daily, orally administered investigational small\nmolecule and potential first benzamide antipsychotic in the United\nStates for the treatment of neuropsychiatric disorders. LB-102 is\na methylated derivative of amisulpride, a widely used\nantipsychotic outside the United States, and LB-102 was developed to\nretain amisulpride’s benefits while addressing its limitations. LB-102 is a\npotent and selective antagonist of D2, D3 and 5HT-7 receptors with few\noff-target effects and broad therapeutic potential across psychosis and\nmood disorders. In early 2025, LB Pharmaceuticals announced positive data\nfrom a four-week placebo-controlled, double-blinded, Phase 2 trial in patients\nwith acute schizophrenia. In this trial, LB-102 demonstrated statistically\nsignificant benefit versus placebo at all doses\nstudied, including rapid onset of effect at week 1 and sustained\nbenefit through the endpoint of the trial, a potentially class-leading\nsafety profile with low rates of EPS (including akathisia), minimal sedation\nand few GI side effects, alongside observed effects on negative symptoms\nand cognitive performance. These data underscore LB-102’s potential to\naddress multiple dimensions of neuropsychiatric illness. The pivotal Phase\n3 NOVA-2 trial of LB-102 for acute schizophrenia and the Phase 2\nILLUMINATE-1 trial of LB-102 for bipolar 1 depression are ongoing, and a\nPhase 2 trial of LB-102 in adjunctive treatment of MDD is\nplanned. Additional expansion opportunities for LB-102\ninclude predominantly negative symptoms of schizophrenia, Alzheimer’s\ndisease psychosis and agitation, as well as other neuropsychiatric\ndiseases. \n\nAbout LB Pharmaceuticals\n\nLB Pharmaceuticals is a neuromedicines company dedicated to developing and\ncommercializing high-impact therapies that address the multiple dimensions of\nunderserved brain diseases. The Company is building a pipeline that leverages\nthe broad therapeutic potential of its lead product candidate, LB-102, which\nthe Company believes has the opportunity to be the first benzamide\nantipsychotic drug approved for neuropsychiatric disorders in the United\nStates. LB-102, if approved, has the potential to become a mainstay of\npsychiatric practice by offering a balanced clinical activity and tolerability\nprofile that provides a potentially attractive alternative to branded and\ngeneric therapeutics for the treatment of a broad range of neuropsychiatric\ndiseases.\n\nCautionary Note Regarding Forward-Looking Statements\n\nStatements contained in this press release regarding matters that are not\nhistorical facts are “forward-looking statements” within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended. Words such\nas “aim,” “anticipate,” “assume,” “believe,”\n“contemplate,” “continue,” “could,” “design,” “due,”\n“estimate,” “expect,” “goal,” “intend,” “may,”\n“objective,” “plan,” “positioned,” “potential,” “predict,”\n“seek,” “should,” “target,” “will,” “would” or similar\nexpressions are intended to identify forward-looking statements. All\nstatements other than statements of historical facts contained in this press\nrelease are forward-looking statements. These forward-looking statements\ninclude, but are not limited to, statements concerning the expected proceeds\nfrom the private placement, expected use of proceeds, and the expected closing\nof the private placement; the expected clinical development and regulatory\npathway and therapeutic benefits of LB-102; the design, objectives,\ninitiation, timing, progress and results of clinical trials of LB-102,\nincluding the pivotal Phase 3 NOVA-2 trial in acute schizophrenia, our open\nlabel trial (NOVA-3), the Phase 2 ILLUMINATE-1 trial in bipolar 1 depression\nand the Phase 2 trial for the adjunctive treatment of MDD and any other trials\nwe may initiate in the future; the Company’s ability to advance its strategy\nto build a fully integrated neuropsychiatric company; and continuing\nadvancement of LB-102 and the Company’s portfolio. Because such statements\nare subject to risks and uncertainties, actual results may differ materially\nfrom those expressed or implied by such forward-looking statements. These\nrisks and uncertainties include, among others: the Company’s limited\noperating history and historical losses; the Company’s ability to raise\nadditional funding to complete the development and any commercialization of\nLB-102; the Company’s dependence on the success of its lead product\ncandidate, LB-102; the Company’s ability to obtain regulatory approval of\nand successfully commercialize its product candidate; the early stages of\nclinical development of the Company’s lead product candidate, LB-102; any\nundesirable side effects or other properties of the Company’s product\ncandidate; that the Company may be delayed in initiating, enrolling or\ncompleting any clinical trials; competition from third parties that are\ndeveloping products for similar uses; the Company’s ability to obtain,\nmaintain and protect its intellectual property; and the Company’s dependence\non third parties in connection with manufacturing, clinical trials and\npreclinical studies.\n\nThese and other risks are described more fully in the section titled “Risk\nFactors” in the Company’s Quarterly Report on Form 10-Q for the quarter\nended March 31, 2026 and its other documents to be subsequently filed with or\nfurnished to the Securities and Exchange Commission. All forward-looking\nstatements contained in this press release speak only as of the date on which\nthey were made. Except to the extent required by law, the Company undertakes\nno obligation to update such statements to reflect events that occur or\ncircumstances that exist after the date on which they were made.\n\nMedia and Investor Contact: \nEllen Rose\nerose@lbpharma.us\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/90903161-520e-409f-b2ac-dd18677b4bb8)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8sTRmH","title":"LB Pharmaceuticals Announces $150 Million Private Placement","author":"Globe Newswire","ticker":"LBRX","created":"2026-07-29T12:00:01.082Z","tickers":["LBRX"],"exchange":"NASDAQ","article_body":"NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB\nPharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines\ncompany dedicated to developing and commercializing high-impact therapies that\naddress the multiple dimensions of underserved brain diseases, today announced\nthat it has entered into a securities purchase agreement to sell 3,577,560\nshares of its common stock and pre-funded warrants to purchase up to 715,513\nshares of its common stock to a limited group of institutional investors in a\nprivate placement. The purchase price of each share of common stock is $34.94.\nThe purchase price of each pre-funded warrant is $34.9399, which represents\nthe per share purchase price for the common stock less the $0.0001 per share\nexercise price for such pre-funded warrant. LB Pharmaceuticals anticipates the\ngross proceeds from the private placement to be approximately $150 million,\nbefore deducting any transaction-related expenses. The private placement is\nexpected to close on or about July 30, 2026, subject to the satisfaction of\ncustomary closing conditions.\n\nThe financing includes participation from new and existing institutional\ninvestors, including Adage Capital Partners, L.P., BB Biotech, Caligan\nPartners, Commodore Capital, Deep Track Capital, funds managed by Farallon\nCapital Management, Integral Health Asset Management, Janus Henderson\nInvestors, Spruce Street Capital, StemPoint Capital LP, a leading mutual fund\nand other investors.\n\nLeerink Partners and Piper Sandler acted as placement agents for the private\nplacement.\n\nLB Pharmaceuticals intends to use the net proceeds from the private placement\nto fund pipeline expansion of LB-102 into new indications with strong\nmechanistic rationale and validating clinical and real-world experience from\namisulpride, potentially including negative symptoms of schizophrenia and\nAlzheimer’s disease agitation/psychosis, and for working capital and general\ncorporate purposes.\n\nThe offer and sale of the securities to be sold in the private placement have\nnot been registered under the Securities Act of 1933, as amended (the\n“Securities Act”), or any state or other applicable jurisdiction’s\nsecurities laws, and such securities may not be offered or sold in the United\nStates absent registration or an applicable exemption from the registration\nrequirements of the Securities Act and applicable state or other\njurisdictions’ securities laws. Concurrently with entering into the\nsecurities purchase agreement, LB Pharmaceuticals and the investors entered\ninto a registration rights agreement pursuant to which LB Pharmaceuticals has\nagreed to file a registration statement with the Securities and Exchange\nCommission registering the resale of the shares of common stock issued in the\nprivate placement, including the shares of common stock underlying the\npre-funded warrants.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any jurisdiction in which such offer, solicitation or sale would\nbe unlawful prior to the registration or qualification under the securities\nlaws of any such jurisdiction.\n\nAbout LB-102\n\nLB-102 is a novel, once-daily, orally administered investigational small\nmolecule and potential first benzamide antipsychotic in the United\nStates for the treatment of neuropsychiatric disorders. LB-102 is\na methylated derivative of amisulpride, a widely used\nantipsychotic outside the United States, and LB-102 was developed to\nretain amisulpride’s benefits while addressing its limitations. LB-102 is a\npotent and selective antagonist of D2, D3 and 5HT-7 receptors with few\noff-target effects and broad therapeutic potential across psychosis and\nmood disorders. In early 2025, LB Pharmaceuticals announced positive data\nfrom a four-week placebo-controlled, double-blinded, Phase 2 trial in patients\nwith acute schizophrenia. In this trial, LB-102 demonstrated statistically\nsignificant benefit versus placebo at all doses\nstudied, including rapid onset of effect at week 1 and sustained\nbenefit through the endpoint of the trial, a potentially class-leading\nsafety profile with low rates of EPS (including akathisia), minimal sedation\nand few GI side effects, alongside observed effects on negative symptoms\nand cognitive performance. These data underscore LB-102’s potential to\naddress multiple dimensions of neuropsychiatric illness. The pivotal Phase\n3 NOVA-2 trial of LB-102 for acute schizophrenia and the Phase 2\nILLUMINATE-1 trial of LB-102 for bipolar 1 depression are ongoing, and a\nPhase 2 trial of LB-102 in adjunctive treatment of MDD is\nplanned. Additional expansion opportunities for LB-102\ninclude predominantly negative symptoms of schizophrenia, Alzheimer’s\ndisease psychosis and agitation, as well as other neuropsychiatric\ndiseases. \n\nAbout LB Pharmaceuticals\n\nLB Pharmaceuticals is a neuromedicines company dedicated to developing and\ncommercializing high-impact therapies that address the multiple dimensions of\nunderserved brain diseases. The Company is building a pipeline that leverages\nthe broad therapeutic potential of its lead product candidate, LB-102, which\nthe Company believes has the opportunity to be the first benzamide\nantipsychotic drug approved for neuropsychiatric disorders in the United\nStates. LB-102, if approved, has the potential to become a mainstay of\npsychiatric practice by offering a balanced clinical activity and tolerability\nprofile that provides a potentially attractive alternative to branded and\ngeneric therapeutics for the treatment of a broad range of neuropsychiatric\ndiseases.\n\nCautionary Note Regarding Forward-Looking Statements\n\nStatements contained in this press release regarding matters that are not\nhistorical facts are “forward-looking statements” within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended. Words such\nas “aim,” “anticipate,” “assume,” “believe,”\n“contemplate,” “continue,” “could,” “design,” “due,”\n“estimate,” “expect,” “goal,” “intend,” “may,”\n“objective,” “plan,” “positioned,” “potential,” “predict,”\n“seek,” “should,” “target,” “will,” “would” or similar\nexpressions are intended to identify forward-looking statements. All\nstatements other than statements of historical facts contained in this press\nrelease are forward-looking statements. These forward-looking statements\ninclude, but are not limited to, statements concerning the expected proceeds\nfrom the private placement, expected use of proceeds, and the expected closing\nof the private placement; the expected clinical development and regulatory\npathway and therapeutic benefits of LB-102; the design, objectives,\ninitiation, timing, progress and results of clinical trials of LB-102,\nincluding the pivotal Phase 3 NOVA-2 trial in acute schizophrenia, our open\nlabel trial (NOVA-3), the Phase 2 ILLUMINATE-1 trial in bipolar 1 depression\nand the Phase 2 trial for the adjunctive treatment of MDD and any other trials\nwe may initiate in the future; the Company’s ability to advance its strategy\nto build a fully integrated neuropsychiatric company; and continuing\nadvancement of LB-102 and the Company’s portfolio. Because such statements\nare subject to risks and uncertainties, actual results may differ materially\nfrom those expressed or implied by such forward-looking statements. These\nrisks and uncertainties include, among others: the Company’s limited\noperating history and historical losses; the Company’s ability to raise\nadditional funding to complete the development and any commercialization of\nLB-102; the Company’s dependence on the success of its lead product\ncandidate, LB-102; the Company’s ability to obtain regulatory approval of\nand successfully commercialize its product candidate; the early stages of\nclinical development of the Company’s lead product candidate, LB-102; any\nundesirable side effects or other properties of the Company’s product\ncandidate; that the Company may be delayed in initiating, enrolling or\ncompleting any clinical trials; competition from third parties that are\ndeveloping products for similar uses; the Company’s ability to obtain,\nmaintain and protect its intellectual property; and the Company’s dependence\non third parties in connection with manufacturing, clinical trials and\npreclinical studies.\n\nThese and other risks are described more fully in the section titled “Risk\nFactors” in the Company’s Quarterly Report on Form 10-Q for the quarter\nended March 31, 2026 and its other documents to be subsequently filed with or\nfurnished to the Securities and Exchange Commission. All forward-looking\nstatements contained in this press release speak only as of the date on which\nthey were made. Except to the extent required by law, the Company undertakes\nno obligation to update such statements to reflect events that occur or\ncircumstances that exist after the date on which they were made.\n\nMedia and Investor Contact: \nEllen Rose\nerose@lbpharma.us\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/90903161-520e-409f-b2ac-dd18677b4bb8)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-29T12:00:01.614936085Z","server_sent_at_ms":1785326401614},"received_at":"2026-07-29T12:00:01.663Z","source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335173/0/en/lb-pharmaceuticals-announces-150-million-private-placement.html"},"analysis":{"id":"90955","press_release_id":"101932","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"LB Pharmaceuticals announced a $150 million private placement, selling 3.58 million shares of common stock and pre-funded warrants for 715,513 shares at a price of $34.94 per share.\n\nProceeds from the financing will be used to fund pipeline expansion of LB-102 into new indications, including negative symptoms of schizophrenia and Alzheimer's disease agitation, as well as for working capital.\n\nLeerink Partners and Piper Sandler acted as placement agents for the offering, which is expected to close on or about July 30, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"LB Pharmaceuticals secures $150M to advance LB-102 pipeline."},"keyFigures":{"dealValueUsd":150000000,"offeringPrice":34.94},"quotedText":"","namedEntities":{"people":[],"products":["LB-102","amisulpride"],"companies":[{"name":"LB Pharmaceuticals Inc.","ticker":"LBRX"},{"name":"Leerink Partners","relationship":"placement agent"},{"name":"Piper Sandler","relationship":"placement agent"},{"name":"Adage Capital Partners, L.P.","relationship":"investor"},{"name":"BB Biotech","relationship":"investor"},{"name":"Janus Henderson Investors","relationship":"investor"}],"dollarAmounts":[{"amount":"$150 million","context":"anticipated gross proceeds from private placement"},{"amount":"$34.94","context":"purchase price per share of common stock"},{"amount":"$34.9399","context":"purchase price per pre-funded warrant"},{"amount":"$0.0001","context":"per share exercise price for pre-funded warrant"}]},"materialImpact":{"score":3,"reasoning":"Significant $150 million capital raise to fund pipeline expansion and extend runway, though it involves the sale of common stock and warrants."},"tickerRelevance":{"others":[],"primary":"LBRX"},"globalImportance":35,"audienceRelevance":20,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small/mid-cap","eventGravity":"private_placement_financing","sectorWeight":"health_care"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"neutral","material_impact_score":3,"narrative":"LB Pharmaceuticals announced a $150 million private placement, selling 3.58 million shares of common stock and pre-funded warrants for 715,513 shares at a price of $34.94 per share.\n\nProceeds from the financing will be used to fund pipeline expansion of LB-102 into new indications, including negative symptoms of schizophrenia and Alzheimer's disease agitation, as well as for working capital.\n\nLeerink Partners and Piper Sandler acted as placement agents for the offering, which is expected to close on or about July 30, 2026.","key_figures":{"dealValueUsd":150000000,"offeringPrice":34.94},"named_entities":{"people":[],"products":["LB-102","amisulpride"],"companies":[{"name":"LB Pharmaceuticals Inc.","ticker":"LBRX"},{"name":"Leerink Partners","relationship":"placement agent"},{"name":"Piper Sandler","relationship":"placement agent"},{"name":"Adage Capital Partners, L.P.","relationship":"investor"},{"name":"BB Biotech","relationship":"investor"},{"name":"Janus Henderson Investors","relationship":"investor"}],"dollarAmounts":[{"amount":"$150 million","context":"anticipated gross proceeds from private placement"},{"amount":"$34.94","context":"purchase price per share of common stock"},{"amount":"$34.9399","context":"purchase price per pre-funded warrant"},{"amount":"$0.0001","context":"per share exercise price for pre-funded warrant"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-29T15:29:10.747Z","global_importance":35,"audience_relevance":20,"importance_components":{"tickerTier":"small/mid-cap","eventGravity":"private_placement_financing","sectorWeight":"health_care"}},"durationMs":244666,"modelName":"glm-4.7"}}